Treatments for Diffuse Large B-cell Lymphoma in Elderly Patients
the Cancer Therapy Advisor take:
Patients older than 80 are less likely to receive the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as treatment for diffuse large B-cell lymphoma (DLBCL), according to an article published online in Cancer.
Data was provided from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Characterization was complete according to presentation, treatment, and survival patterns in patients diagnosed with DLBCL between 2002 and 2009.
Of the 4,635 patients included, 1,156 (25%) were older than 80. Instead of receiving R-CHOP, the patients over 80 years were more likely to be observed or receive the combination of rituximab, cyclophosphamide, vincristine, and prednisone (P<0.0001 for both).
Through multivariable Cox proportional hazards models, the R-CHOP therapy regimen was determined to be the only regimen associated with improved overall survival (hazard ratio, 0.45; 95% confidence interval: 0.33-0.62) and lymphoma-related survival (hazard ratio, 0.58; 95% confidence interval: 0.38-0.88).
The study suggests that R-CHOP be considered as a regimen for patients older than 80 years and further studies be conducted on the correlation of treatment of DLBCL and the quality of life of these patients.
Elderly patients less likely to receive combination R-CHOP for lymphoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia